PT - JOURNAL ARTICLE AU - de Oliveira, Tulio AU - Lutucuta, Silvia AU - Nkengasong, John AU - Morais, Joana AU - Paixão, Joana Paula AU - Neto, Zoraima AU - Afonso, Pedro AU - Miranda, Julio AU - David, Kumbelembe AU - Inglês, Luzia AU - Raisa Rivas Carralero, Amilton Pereira Agostinho Paulo AU - Freitas, Helga Reis AU - Mufinda, Franco AU - Tessema, Sofonias Kifle AU - Tegally, Houriiyah AU - San, Emmanuel James AU - Wilkinson, Eduan AU - Giandhari, Jennifer AU - Pillay, Sureshnee AU - Giovanetti, Marta AU - Naidoo, Yeshnee AU - Katzourakis, Aris AU - Ghafari, Mahan AU - Singh, Lavanya AU - Tshiabuila, Derek AU - Martin, Darren AU - Lessells, Richard J TI - A novel variant of interest of SARS-CoV-2 with multiple spike mutations detected through travel surveillance in Africa AID - 10.1101/2021.03.30.21254323 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.30.21254323 4099 - http://medrxiv.org/content/early/2021/04/04/2021.03.30.21254323.short 4100 - http://medrxiv.org/content/early/2021/04/04/2021.03.30.21254323.full AB - At the end of 2020, the Network for Genomic Surveillance in South Africa (NGS-SA) detected a SARS-CoV-2 variant of concern (VOC) in South Africa (501Y.V2 or PANGO lineage B.1.351)1. 501Y.V2 is associated with increased transmissibility and resistance to neutralizing antibodies elicited by natural infection and vaccination2,3. 501Y.V2 has since spread to over 50 countries around the world and has contributed to a significant resurgence of the epidemic in southern Africa. In order to rapidly characterize the spread of this and other emerging VOCs and variants of interest (VOIs), NGS-SA partnered with the Africa Centres for Disease Control and Prevention and the African Society of Laboratory Medicine through the Africa Pathogen Genomics Initiative to strengthen SARS-CoV-2 genomic surveillance across the region.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for genomics surveillance was provided by the South African Medical Research Council (SAMRC), the South African Department of Science and Innovation (DSI), the Africa Centres for Disease Control and Prevention (Africa CDC) and the African Society of Laboratory Medicine (ASLM) through the Africa Pathogen Genomics Initiative (Africa PGI)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:he project was approved by University of KwaZulu-Natal Biomedical Research Ethics Committee. Protocol reference number: BREC/00001195/2020. Project title: COVID-19 transmission and natural history in KwaZulu-Natal, South Africa: Epidemiological Investigation to Guide Prevention and Clinical Care. Patient consent was not required for the genomic surveillance. This requirement was waived by the Research Ethics Committees.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll of the sequences are available at GISAID. All of the short reads are available at the Short Read Archive (SRA) of the National Centre for Biotechnology Information (NCBI) (Bioproject Accession: PRJNA717113). https://www.krisp.org.za